The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer

PURPOSE: To better understand the efficacy and safety of anti-PD-1/PD-L1 therapy (atezolizumab, pembrolizumab, nivolumab) in patients with previously treated advanced non-small-cell lung cancer (NSCLC). METHODS: The Cochrane Controlled Trial Register, Embase, Medline, and the Science Citation Index...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Zhixin, Zhu, Xu, Sun, Yanhua, Zhang, Yanxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593686/
https://www.ncbi.nlm.nih.gov/pubmed/28915714
http://dx.doi.org/10.18632/oncotarget.18406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593686/
https://www.ncbi.nlm.nih.gov/pubmed/28915714
http://dx.doi.org/10.18632/oncotarget.18406

Ejemplares similares